12:00 AM
 | 
Oct 01, 2012
 |  BC Week In Review  |  Company News  |  Other News

Progenics cancer, infectious, gastrointestinal news

For the second time in 13 months, Progenics restructured and will focus on its cancer pipeline. The company reduced headcount by 27 (26%) to 77. The move comes after the company received a July complete response letter from FDA for an sNDA for subcutaneous Relistor methylnaltrexone to treat opioid-induced constipation (OIC) in patients with non-cancer pain (see BioCentury, Aug. 6).

The company said the...

Read the full 312 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >